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AMPARs mediate the vast majority of fast excitatory synaptic transmission in the brain
and their biophysical and trafficking properties depend on their subunit composition and
on several posttranscriptional and posttranslational modifications. Additionally, in the brain
AMPARs associate with auxiliary subunits, which modify the properties of the receptors.
Despite the abundance of AMPAR partners, recent proteomic studies have revealed
even more interacting proteins that could potentially be involved in AMPAR regulation.
Amongst these, carnitine palmitoyltransferase 1C (CPT1C) has been demonstrated to
form an integral part of native AMPAR complexes in brain tissue extracts. Thus, we
aimed to investigate whether CPT1C might be able to modulate AMPAR function.
Firstly, we confirmed that CPT1C is an interacting protein of AMPARs in heterologous
expression systems. Secondly, CPT1C enhanced whole-cell currents of GluA1 homomeric
and GluA1/GluA2 heteromeric receptors. However, CPT1C does not alter the biophysical
properties of AMPARs and co-localization experiments revealed that AMPARs and CPT1C
are not associated at the plasma membrane despite a strong level of co-localization at
the intracellular level. We established that increased surface GluA1 receptor number
was responsible for the enhanced AMPAR mediated currents in the presence of CPT1C.
Additionally, we revealed that the palmitoylable residue C585 of GluA1 is important in the
enhancement of AMPAR trafficking to the cell surface by CPT1C. Nevertheless, despite
its potential as a depalmitoylating enzyme, CPT1C does not affect the palmitoylation state
of GluA1. To sum up, this work suggests that CPT1C plays a role as a novel regulator of
AMPAR surface expression in neurons. Fine modulation of AMPAR membrane trafficking
is fundamental in normal synaptic activity and in plasticity processes and CPT1C is
therefore a putative candidate to regulate neuronal AMPAR physiology.
Keywords: glutamate receptors, GluA1, CPT1C, AMPAR trafficking, surface expression, electrophysiological
recordings, cortical neurons, palmitoylation
INTRODUCTION
Glutamate is the neurotransmitter involved in the majority of
excitatory synaptic processes in the brain. This amino acid acti-
vates primarily ionotropic glutamate receptors (iGluRs): NMDA,
AMPA, and Kainate receptors. Amongst iGluRs, the AMPA
receptors (AMPARs) are essential as they mediate 90% of the
fast excitatory neurotransmission in the central nervous system
(CNS). Although their main role relates to synaptic transmis-
sion, AMPARs are also responsible for some forms of activity-
dependent synaptic plasticity, the process thought to underlie
higher order cognitive functions such as learning and memory
(Barry and Ziff, 2002; Malinow and Malenka, 2002; Song and
Huganir, 2002; Bredt and Nicoll, 2003).
AMPARs are tetrameric structures formed by four differ-
ent subunits: GluA1–A4 and can be found as homo- or hete-
rotetrameric structures (Traynelis et al., 2010), heteromeric
receptors being the most common combinations found in neu-
rons, amongst different brain regions (Gallo et al., 1992; Kondo
et al., 1997; Lu et al., 2009; Reimers et al., 2011). Their subunit
composition is crucial for AMPAR properties and their roles
in neurons largely rely on the different intracellular carboxyl-
terminal (C-terminal) domains, which vary between subunits.
AMPAR subunits can be found with long (GluA1, GluA2-long,
and GluA4) or short (GluA2, GluA3, and GluA4-short) intra-
cellular C-terminal domains (Köhler et al., 1994). The differ-
ent C-termini of AMPAR subunits permit a great variability
in protein-to-protein interactions dependant on both the dis-
tinct AMPAR subunits (Palmer et al., 2005) and the class of
PDZ binding domain (Sheng and Sala, 2001; Cai et al., 2002).
The C-terminal domain of GluA subunits also contains most of
the well-characterized phosphorylation and palmitoylation sites.
These posttranslational modifications allow a fine and complex
regulation of AMPARs through the specific interaction of the
receptor with multiple intracellular proteins, which play crucial
roles in AMPAR trafficking and function (Anggono and Huganir,
2012; Lu and Roche, 2012).
Of themultiple proteins that transiently interact with AMPARs
and that determine their trafficking, synaptic targeting and
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recycling in neurons, some special attention must be given to
transmembrane proteins that form integral part of the func-
tional receptor. In addition to trafficking, these proteins modulate
channel gating properties hence acting as genuine auxiliary sub-
units of the AMPARs. Amongst these, the most important are the
Transmembrane AMPA receptor Regulatory Proteins (TARPs; Kato
et al., 2010a; Straub and Tomita, 2012). Indeed, the vast majority
of AMPARs in the CNS are associated with TARPs (Menuz et al.,
2008; but see Schwenk et al., 2009) and they appear to be crucial
for correct trafficking and synaptic targeting (Tomita et al., 2005).
Depending on the TARP subtype, AMPAR trafficking properties
are differentially modulated resulting in a differential synaptic
integration (Jackson and Nicoll, 2011).
A recent proteomic study confirming the interaction of
AMPARs with transient and integral partners of AMPARs has
also identified a number of proteins capable of interacting with
AMPAR subunits. One of them is Carnitine palmitoyltransferase
1C (CPT1C), which forms part of some macromolecular com-
plexes of AMPARs in the brain (Schwenk et al., 2012). This
protein is a member of Carnitine palmitoyltransferases, a fam-
ily of enzymes that catalyzes the exchange of acyl groups between
carnitine and CoA to facilitate the transport of long chain fatty
acids from the cytoplasm to the mitochondria for β-oxidation
(McGarry and Brown, 1997). CPT1C is a specific CPT1 brain
isoform strongly expressed in the hypothalamus, the hippocam-
pus, cortex, and cerebellum (Price et al., 2002). CPT1C is highly
homologous to the other CPT1s: it has the ability to bind
palmitoyl-CoA andmaintains the same binding affinity as CPT1A
for malonyl-CoA (the endogenous allosteric CPT1 inhibitor).
However, CPT1C has a 100-fold lower catalytic activity than the
other isoforms (Sierra et al., 2008). Moreover, it is located in the
endoplasmic reticulum (ER) instead of the mitochondria (Sierra
et al., 2008; Carrasco et al., 2012). The molecular mechanism of
CPT1C action has not been unraveled yet, but some clues about
its importance in mammalian brain function derive from CPT1C
knockout mice studies. These KO mice show an impairment of
motor functions, muscle strength, hypoactivity (Carrasco et al.,
2013), behavioral learning deficits (Carrasco et al., 2012) and
altered maturation of dendritic spines in hippocampal neurons
indicating an important role of CPT1C in the CNS. Additionally,
some results indicate that CPT1C is also involved in the control
of food intake and energy expenditure (Wolfgang et al., 2006). It
has also been described that a gain-of-function of CPT1C in the
brain of transgenic mice results in severe growth retardation and
in a reduction of brain weight (Reamy and Wolfgang, 2011).
In the present study we investigate whether CPT1C might
affect AMPAR function. Our results confirm that GluA subunits
are able to interact with CPT1C and this interaction modulates
AMPAR surface expression in a subunit-dependentmanner, with-
out altering the gating properties of the receptor. Moreover we
find that the palmitoylable cysteine residue located in the 585
position of GluA1 is crucial for CPT1C modulation of AMPAR
surface level. Since it is clear that regulation of AMPARmembrane
trafficking is critical for normal synaptic activity and for sev-
eral forms of synaptic plasticity in the brain, the involvement of
CPT1C in these processes is relevant for understanding AMPAR
physiology.
MATERIALS AND METHODS
EXPRESSION CONSTRUCTS
AMPAR subunit cDNAs were a gift from Prof. Dr. Stephen
Heinemann (Salk Institute, La Jolla, CA) and Prof. Dr. Peter
Seeburg (Max Planck Institute, Heidelberg, Germany). pDs-
Red-ER-KDEL was a generous gift of Juan Pablo Muñoz (IRB,
Barcelona). GluA1-pIRES-mCherry: a pIRES vector expressing
GluA1 and mCherry translated from a single bicistronic mRNA
(used for heteromeric GluA1/GluA2 electrophysiological exper-
iments). CPT1C plasmid vectors were a generous gift from
Dr. Núria Casals (Universitat Internacional de Catalunya) and
CPT1A-GFP was a gift from Dr. Dolors Serra (Universitat de
Barcelona). Characteristics of CPT1C and CPT1A plasmid vec-
tors were: (1) CPT1C-GFP: a plasmid containing CPT1C cDNA
sequence C-terminally tagged with EGFP; this construct produces
a protein of approximately 100 kDa (all experiments involving
CPT1C have been performed with this plasmid unless otherwise
stated); (2) CPT1C-pIRES: a pIRES vector expressing CPT1C and
EGFP translated from a single bicistronic mRNA and (3) CPT1A-
GFP: contains CPT1A cDNA sequence C-terminally tagged with
EGFP. All cDNAs are from rat and plasmid vectors are all under
the control of the same promoter (CMV promoter).
To obtain GluA1 cDNAs with mutations in the palmi-
toylation sites we used site-directed mutagenesis to change
specific base pairs. Primers containing the mutation/s were
designed and then synthetized by Integrated DNA Technologies
(IDT). GluA1(C585S) and GluA1(C811S) mutant cDNAs
resulted from changing the codon TGT to TCT and TGC
to TCC, respectively. Both changes produce a cysteine to
serine switch making these palmitoylation targets disap-
pear. For the double mutant GluA1(C585,811S) we used
GluA1(C585S) cDNA as a template and introduced the
C811S mutation to create the GluA1(C585,811S) product, in
which both palmitoylation sites from GluA1 were eliminated.
The primers used for introducing the mutations were the
following:
C585S: AAGGATCTGACATTTCCCCCAGGTCCC
C811S: CCTTAATCGAGTTCTCCTACAAATCCCGTAGCG
All constructs were fully sequenced to verify sequence integrity.
CELL CULTURE AND TRANSFECTION
tsA201 cells – derived from HEK293, which do not express
CPT1C protein (Sierra et al., 2008)—were maintained in
DMEM:F12 containing 10% fetal bovine serum and 1%
penicillin–streptomycin solution in 5% CO2/95% air at 37◦C.
24 h before transfection, 1.5 × 106 cells were plated into
T25 flasks for coimmunoprecipitation (Co-IP) and Acyl
Biotin Exchange assays (ABE) or 0.5 × 105 cells onto poly-
D-lysine-coated coverslips for immunofluorescence (IF) and
electrophysiological (EP) experiments. Cells were transiently
co-transfected with 5.4μg total cDNA (for Co-IP and ABE)
and 0.6μg total cDNA (for IF and EP) using X-tremeGENE
transfection reagent (Roche) according to the manufactur-
ers’ directions. In all transfections the ratio used was 1:2
(GluA:CPT1C). Media was replaced 24 h after transfection
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with fresh media containing 2,3-dioxo-6-nitro-1,2,3,4-
tetrahydrobenzo[f]quinoxaline-7-sulfonamide 50μM (NBQX;
Tocris-ABCam, Abcam) to prevent AMPAR-mediated toxicity.
For EP experiments, cells were re-plated on glass coverslips to
allow optimal density. All experiments were performed 48 h later.
NEURONAL CULTURES AND TRANSFECTION
Cortical neuron cultures were prepared from mouse embryos
(E18). The cerebral cortex was isolated and maintained in cold
Hank’s Balanced Salt Solution (HBSS, Gibco) supplemented
with 0.45 % glucose. After removal of the meninges, the corti-
cal tissue was digested mildly with trypsin for 17min at 37◦C
and mechanically dissociated. Cells were washed three times in
HBSS and resuspended in Neurobasal medium supplemented
with 2mM Glutamax (Gibco) before filtering in 70μm mesh
filters (BD Falcon). Cells were plated onto glass coverslips (5 ×
104 cells/cm2) coated with 0.1mg/ml poly-L-lysine (Sigma). 2 h
after seeding, the plating medium was replaced by complete
growth medium (Neurobasal medium supplemented with 2%
B27 (Invitrogen) and 2mM Glutamax) and the coverslips were
incubated at 37◦C in a humidified 5 % CO2 atmosphere. Every
3–4 days, half of the conditioned medium was removed and
replaced by fresh growth medium. Primary cultures were trans-
fected with Lipofectamine 2000 on day 7 in vitro (7DIV), accord-
ing to the manufacturer’s, instructions and the cells were fixed
72 h after transfection. All the experimental procedures were
carried out according to European Union guidelines (Directive
2010/63/EU) and following protocols that were approved by the
Ethics Committee of the Bellvitge Biomedical Research Institute
(IDIBELL).
COIMMUNOPRECIPITATION
48 h after transfection, tsA201 cells were washed twice with room
temperature PBS and collected in 1ml 50mM Tris-HCl (pH 7.4)
with Protease Inhibitor cocktail (Sigma) on ice. All subsequent
steps were performed at 4◦C. Cells were lysed in a Polytron (VDI
12; VWR) at force 5, for 20 s, twice. Lysates were centrifuged
at 1000 ×g for 10min to pellet nuclei and unlysed cells. The
supernatant was further centrifuged at 20,000 ×g for 30min,
and the membrane fraction (pellet) was resuspended in solu-
bilisation buffer (1 % Triton X-100, 150mM NaCl and 50mM
Tris-HCl pH 8, containing protease inhibitors) and homogenized
with a Polytron for 20 s. After 20min on ice, insoluble mate-
rial was pelleted with a 30min centrifugation at 20,000 ×g and
the supernatant was quantified using the BCA method (Thermo
Scientific). 200–400μg of total protein were incubated with
4μg of antibody overnight at 4◦C with orbital agitation (anti-
bodies: mouse anti-GluA1-NT (N-terminus), rabbit anti-GluA2
(cytoplasmic domain) both from Merck Millipore, rabbit serum
anti-GFP from Invitrogen). Antibody-protein complexes were
pulled down by incubating with 80μl of Protein-A sepharose
beads (Sigma) pre-equilibrated with solubilisation buffer, for 2 h.
Precipitated complexes were washed in solubilisation buffer three
times and eluted with 2× SDS/DTT sample buffer, heated 10min
at 76◦C and separated on SDS/PAGE. Before adding the antibod-
ies, 10% of total protein (100μl) was removed as input samples.
500μl of pre-cooled acetone was added to the input samples, the
mixture was vortexed and incubated overnight at −20◦C. The
precipitated proteins were cleared by centrifugation at 20,000 ×g
for 20min, supernatant was removed, and pellets were air-dried
for 15–30min and resuspended with appropriate volume of 2 ×
SDS/DTT buffer.
IMMUNOBLOTTING
Samples were separated by SDS/PAGE in 4-15% mini-protean
TGX precast gels, transferred using Trans-Blot Turbo transfer sys-
tem on nitrocellulose membranes (all from BioRad). Membranes
were blocked in TBS with 0.1% Tween 20 (TBS-T) containing 5%
(wt/vol) BSA or non-fat skim milk. Peroxidase-conjugated sheep
anti-mouse or donkey anti-rabbit secondary antibodies (Dako)
diluted in blocking solution at 1:1000 dilution, were detected by
using ECL reagent (Amersham) and a LAS3000 Intelligent Dark
Box (Fujifilm) was used to report western-blots. Quantification of
the western blots was performed with Image J (NIH).
IMMUNOCYTOCHEMISTRY
Immunofluorescence was performed in tsA201 cells grown on
lysine treated coverslips, 48 h after transfections. Washes were
always performed by immersion of the coverslips in PBS or PBS-G
(20mM Glycine in PBS). Composition of different solutions:
Fixation solution (2% PFA in PBS), permeabilization solution
(0.1% Triton X-100 in PBS-G), blocking solution (10% NGS,
2% BSA, 0.1% Triton X-100 in PBS-G), antibody incubation
solution (4% normal goat serum and 0.1% BSA in PBS-G) and
triton-antibody solution (antibody incubation solution contain-
ing 0.1% Triton X-100). Antibodies incubations were performed
in a humid chamber at 37◦C for 1 h.
For co-localization of CPT1C with GluA1 or GluA2 and for
determining the level of surface expression of GluA1 in tsA201,
the following method was used: staining surface AMPARs was
achieved by labeling live cells with the mouse anti-GluA1-NT or
mouse anti-GluA2 antibodies (both from Merck Millipore) in
a 1:200 solution in DMEM:F12, for 7–10min at 37◦C. In neu-
ronal cultures, the surface staining step was performed for 1 h at
37◦C on fixed neurons (4% PFA + 4% sucrose). After washes in
room temperature PBS, tsA201 cells were fixed for 15min at room
temperature and incubated with goat anti-mouse Alexafluor 555
(Molecular Probes) at 1:250 in antibody incubation solution.
After several washes in PBS-G, cells were fixed again to preserve
the binding of the first secondary antibody. Cells were subse-
quently permeabilized for 5–10min and blocked for 30min. Next,
and in order to determine the total expression of AMPARs in each
cell, GluA1 or GluA2 were labeled incubating the coverslips with
the same mouse anti-GluA1-NT or mouse anti-GluA2 antibod-
ies at 1:200 (in triton-antibody incubation solution). Following
washes in PBS-G, cells were incubated with goat anti-mouse
Alexafluor 647 (Molecular Probes) at 1:500 (in triton-antibody
incubation solution). Coverslips were then washed and mounted
with Fluoromount (Invitrogen).
For co-localization of CPT1C with GM-130 (Golgi marker),
cells were transfected with CPT1C-GFP and Golgi staining was
performed on fixed, permeabilized and blocked tsA201 cells by
incubating cells with mouse anti-GM-130 (BD-Biosciences) at
1:50 in triton-antibody incubation solution and subsequently
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with goat anti-mouse Alexafluor 555 (Molecular Probes) at
1:500.
For co-localization of CPT1C with an ER marker we co-
transfected tsA201 cells with 600 ng of total DNA at a ratio of
1:2 (ER-KDEL: CPT1C). 48h after transfection cells were fixed for
15min in 4% PFA, washed and mounted in Fluoromount.
CONFOCAL IMAGING AND IMMUNOFLUORESCENCE QUANTIFICATION
Confocal images were acquired on a spectral confocal microscope
(Leica TCS-SL, CCiTUB), using 40× or 63× oil objective lenses,
in multitracking mode to minimize channel crosstalk. Each image
was taken through laser excitation lines 488, 543, and 633 and
Differential Interference Contrast (DIC). For immunofluores-
cence quantification experiments the same settings for each con-
dition and throughout experiments were used. For tsA201 cells,
stacks of 0.7μm were taken from different areas and for cortical
neurons stacks were of 0.3μm.
Quantification of GluA1 surface expression was performed
using Image J (NIH). Each stack was Z-projected to the maxi-
mum intensity. With the freehand selection tool individual cells
or dendrites co-expressing the receptor and CPT1C-GFP or
GFP (expression verified by tracking fluorescence intensity in
the green channel) were traced and fluorescence in each chan-
nel was measured. The fluorescence values of each cell/dendrite
were then analyzed, red integrated density (INTDEN) being the
value corresponding to surface expression of the receptor in that
cell/dendrite, and blue INTDEN being the value for total expres-
sion of GluA1 in the same cell/dendrite (tsA201 cells with low
levels of blue fluorescence were not quantified). The mean back-
ground intensity was obtained from three different areas of each
image and subtracted from eachmeasurement using the following
formula:
CTCF = INTDEN − (AREA∗ MEAN FLUORESC BKGD) (1)
where CTCF stands for corrected total cell fluorescence. Then,
the ratio surface to total was obtained from the CTCF value
from red fluorescence (surface) divided by the CTCF value from
blue fluorescence (total), and normalized to the reference condi-
tion (GluA1+GFP or GFP transfected neurons). Finally, column
graphics including the mean ratio of each condition were plotted
and the error bars (SEM) were obtained. A set of at least 3 differ-
ent immunofluorescences for each condition was performed and
10–50 cells of each condition were analyzed for each immunoflu-
orescence. For neuronal experiments, three separate independent
cultures were performed and 70 and 80 dendrites from 21 and 23
neurons from control and test condition were analyzed.
Quantification of co-localization was performed using the
Manders Overlap Coefficient (MOC) calculated in Image J via
the JACoP plugin from images of single cells. This coefficient
ranges between 1 and zero with values close to 1 being high
co-localization, and values close to zero being low.
ELECTROPHYSIOLOGY: GENERAL PROCEDURES
Cells were visualized with an inverted microscope (IX50;
Olympus). Electrodes were fabricated from borosilicate glass
(1.5mmo.d., 0.86mm i.d., Harvard Apparatus) pulled with a PC-
10 vertical puller (Narishige). Electrode resistance varied between
configurations (see below). Macroscopic currents were recorded
at room temperature (22-25◦C) in the whole-cell configuration
(wc) or from outside-out patches (o) excised from GFP-positive
cells. Currents were recorded with Axopatch 200B amplifier, fil-
tered at 2 kHz (wc) or 10 kHz (o) and digitized at 5 kHz (wc) or
50 kHz (o) using Digidata 1440A interface with pClamp 10 soft-
ware (Molecular Devices Corporation). For all configurations the
“extracellular” solution contained (in mM): 145 NaCl, 2.5 KCl,
1 CaCl2, 1 MgCl2, 10 glucose and 10 HEPES (pH to 7.42 with
NaOH). For fast agonist application, 10mM glutamate was added
to the “extracellular” solution. The “intracellular” solution con-
tained (in mM): 145 CsCl, 2.5 NaCl, 1 Cs-EGTA, 4 MgATP, and
10 HEPES (pH to 7.2 with CsOH). Spermine tetrahydrochloride
(Sigma Aldrich) was added to intracellular solution at 100μM in
all cases.
WHOLE-CELL RECORDINGS
Whole-cell recordings were made from isolated cells using thick-
walled electrodes with a resistance of 3–5M, giving a final series
resistance of 5–15 M. A voltage ramp protocol was used to
change the holding potential (0 to –80mV then to +80mV at a
rate of 160mV/s; with the voltage held at –80mV for 200ms pre-
vious to the ramp). Receptors were activated by a bath application
of 1mM glutamate plus 25μM cyclothiazide (CTZ) to prevent
receptor desensitization. Control traces were subtracted from sta-
ble agonist-activated responses and the average current recorded
at −80mV was measured. In all recordings, to control for differ-
ences in cell surface area, the response to glutamate was expressed
as current density (–pA/pF; maximum current divided by input
capacitance as measured from the amplifier settings).
The rectification index (RI) was defined as the absolute
value of glutamate-evoked current at +60mV divided by that
at −60mV:
RI + 60mV/ − 60mV = |I+60mV|/|I−60mV| (2)
AGONIST APPLICATION TO EXCISED PATCHES
For out-side out patches we used electrodes with a final resistance
of 8–12M. Rapid agonist application was achieved by switching
between a continuously flowing control solution (extracellular
solution diluted by 4%) and a glutamate-containing solution
(extracellular solution plus 2.5μg/ml sucrose and 10mM gluta-
mate). Solution switching was achieved by piezoelectric trans-
lation of a theta-barrel application tool made from borosilicate
glass (1.5mm o.d.; Sutter Instruments) mounted on a piezoelec-
tric translator (P-601.30; Physik Instrumente). 100ms jumps were
applied to outside-out patches at a holding potential of −60mV.
At the end of each experiment, the adequacy of the solution
exchange was tested by destroying the patch and measuring the
liquid-junction current at the open pipette (10–90% rise time
normally 200–300μs).
The kinetics of desensitization of the glutamate-activated cur-
rents were determined by fitting the glutamate-evoked responses
at Vm −60mV to a double-exponential function in order to
determine the weighted time constant (τw,des):
τw,des = τf
(
Af
Af + As
)
+ τs
(
As
Af + As
)
(3)
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where Af and τf are the amplitude and time constant of
the fast component of desensitization and As and τs are
the amplitude and time constant of the slow component of
desensitization.
NON-STATIONARY FLUCTUATION ANALYSIS (NSFA)
To deduce channel properties from macroscopic responses, glu-
tamate (10mM) was applied to outside-out patches (100ms
duration, 1Hz, Vhold −60mV) and the ensemble variance of
all successive pairs of current responses were calculated. The
single channel current (i) and the total number of channels
in the patch (N) were calculated by plotting this ensemble
variance against mean current (I) and fitting with a parabolic
function:
σ2 = σ2B +
(
iI −
(
I
2
N
))
(4)
where σ2B is the background variance. Along with normal peak-
to-peak variation in the currents due to stochastic channel
gating, some patches presented a gradual decline in peak ampli-
tude. The mean response was calculated from the periods of
the recordings showing stable responses that were identified
using a Spearman rank-order correlation test (Igor Pro with
Neuromatic). The weighted-mean single-channel conductance
was determined from the single-channel current and the hold-
ing potential corrected for the calculated liquid-junction potential
(+4.9mV; pClamp 10).
ACYL-BIOTIN EXCHANGE (ABE) ASSAY
Detection of palmitoylation levels of GluA1 subunits was per-
formed as described in Brigidi and Bamji (2013). 48 h after
transfection, tsA201 cells co-expressing GluA1 and GFP or
GluA1 and CPT1C-GFP, were washed with ice-cold PBS and
lysed with a 30 G syringe 6 times in ice-cold lysis buffer
(1% IGEPAL, 50mM Tris-HCl pH 7.5, 150mM NaCl, 10%
Glycerol, Protease Inhibitor Cocktail (Roche) and PMSF) con-
taining 50mM N-ethylmaleimide (NEM) (Sigma). All steps
where performed at 4◦C. Lysates were cleared by centrifuga-
tion at 16,000 xg for 30min and the amount of protein in the
supernatant was determined using the BCA method (Thermo
Scientific). 750μg – 1.5mg of protein were used for overnight
immunoprecipitation of GluA1 [4μg of anti-GluA1-NT anti-
body (MerckMillipore)]. Then, protein-antibody complexes were
pulled-down with Protein-A sepharose beads (Sigma) for 1–2 h.
The total immunoprecipitate was then resuspended in lysis buffer
with 10mM NEM and it was split into two equivalent samples:
one sample for specific cleavage and unmasking of the palmi-
toylated cysteine’s thiol group by 1M hydroxylamine treatment
(+HAM sample) and a second equivalent sample but with-
out the presence of HAM to control non-specific incorporation
of biotin (-HAM sample). Before performing HAM treatment,
samples were totally washed to avoid any presence of unbound
NEM. 1M HAM solution was prepared in pH 7.2 lysis buffer
and ± HAM treatment was performed for 1 h at room tempera-
ture. After washes, selective labeling of the palmitoylated cysteine
using a thiol-reactive biotinylation reagent, biotin-BMCC (1μM)
(Thermo Scientific) in pH 6.2 lysis buffer was performed for 1 h
at 4◦C in ± HAM samples. Then, the thiol-biotinylated proteins
following the ABE steps were resolved by SDS-PAGE andWestern
Blotting was performed. Membranes were blocked with 3% BSA
in TBS-T and incubated with Streptavidin-HRP (Invitrogen)
(1:5000 from a 1mg/ml stock in 0.3 % BSA). After stripping,
the same membrane was incubated with an anti-GluA1-NT anti-
body (1:1000) to normalize palmitoylation levels to the amount
of immunoprecipitated protein.
ANALYSIS AND STATISTICS
Electrophysiological recordings were analyzed using IGOR Pro
(Wavemetrics Inc.) with NeuroMatic (Jason Rothman, UCL).
Data are presented in the text as the mean ± SEM from n
patches and in the figures as bar plots of the group mean, with
error bars denoting the SEM. Comparisons between two groups
were performed using the non-parametric Mann-Whitney U test.
Differences were considered significant at p < 0.05. Statistical
analysis was performed using GraphPad Prism version 5.0d for
Mac OS X (GraphPad Software, San Diego California USA, www.
graphpad.com).
RESULTS
AMPAR SUBUNITS COIMMUNOPRECIPITATE WITH CPT1C IN
HETEROLOGOUS EXPRESSION SYSTEM
CPT1C has been shown to interact with native AMPAR sub-
units in rat brain tissue (Schwenk et al., 2012). Thus we first
sought to determine if in our expression system CPT1C also
interacted with AMPAR subunits. To analyse the interaction
of GluA1 with CPT1C we performed coimmunoprecipitation
assays from tsA201 cells transiently transfected with GluA1 and
the construct CPT1C tagged with the green fluorescence pro-
tein GFP (CPT1C-GFP; see methods) (Figure 1). Membranes
of these cells were immunoprecipitated either with anti-GluA1
or anti-GFP and subsequently detected using Western blot.
Antibodies recognizing GFP were able to pull down GluA1
when co-expressed with CPT1C-GFP (Figure 1A; upper mid-
dle panel). The ∼100 KDa band was not detected with GluA1
antibody in anti-GFP immunoprecipitates from cells transfected
only with GluA1 or CPT1C-GFP. Additionally, coimmunopre-
cipitation was observed by pulling down CPT1C-GFP with an
anti-GluA1 antibody (Figure 1A; lower right panel). Correct
expression of the different constructs was confirmed by Western
blot of the input samples (Figure 1A; upper and lower left pan-
els). Our results confirm previous observations and indicate
that in tsA201 cells CPT1C physically associates with GluA1
subunit.
Equivalent conditions were used for detecting interaction of
GluA2 with CPT1C and the same negative controls were per-
formed. Figure 1B shows that GluA2 subunit coimmunoprecipi-
tated with CPT1C-GFP when the latter was pulled-down with an
anti-GFP antibody (upper middle panel). Additionally, the anti-
GluA2 antibody was able to pull-down CPT1C (Figure 1B; lower
right panel). The presence of both proteins was detected in the
input samples (Figure 1B; upper and lower left panels). These
results confirm that both GluA1 and GluA2 interact with CPT1C
in tsA201 cells when both proteins are co-expressed.
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FIGURE 1 | GluA1 and GluA2 coimmunoprecipitate with CPT1C in
expression systems. (A) Co-IP of the membranous fraction of tsA201
cells co-expressing either GluA1 alone or together with CPT1C-GFP
confirming the interaction between CPT1C and GluA1. As a negative
control GluA1 was co-expressed with an empty plasmid expressing GFP
alone (pEGFP) and CPT1C-GFP was co-expressed with an empty plasmid
(pcDNA3.0). Transfected cells were lysed and membranes were solubilized.
200-400μg of solubilized membranes was immunoprecipitated with an
anti-GFP antibody (IP: antiGFP) or with anti-GluA1-NT antibody (IP:
antiGluA1). An input sample collected prior to immunoprecipitation of
these extracts is shown as “INPUT.” Inputs and immunoprecipitated
samples were separated using SDS-PAGE and Western Blot was
performed using anti-GluA1-NT (WB: antiGluA1) or anti-GFP (WB: antiGFP)
antibodies. Immunoprecipitations were performed three times. (B) Same
as in (A) but for tsA201 cells expressing GluA2 or GluA2 plus CPT1C-GFP.
Membrane lysates were immunoprecipitated with an anti-GFP antibody (IP:
antiGFP) or a rabbit polyclonal anti-GluA2 (cytoplasmic domain) (IP:
antiGluA2). Western Blots were performed using mouse anti-GluA2 (WB:
antiGluA2) or anti-GFP (WB: antiGFP) antibodies. Immunoprecipitations
were replicated three times.
CPT1C INCREASES WHOLE-CELL CURRENTS OF GluA1-CONTAINING
AMPARs
Previous results (Schwenk et al., 2012) and our coimmunopre-
cipitation experiments suggest that CPT1C and AMPARs form
part of the same complex at some stage either during the biosyn-
thetic pathway or as an integral part of the receptor at the
cell surface. Given that, we wondered if the interaction between
AMPAR subunits and CPT1C could have any functional conse-
quences on AMPARs. To explore that possibility we transiently
transfected tsA201 cells with GluA1 subunit in the absence and
presence of CPT1C-GFP and we measured glutamate-evoked
whole-cell currents at different holding potentials by applying
a voltage ramp in the presence of 1mM glutamate and 25μM
CTZ. Figures 2A,B illustrate two examples of currents recorded
between −80 and +80mV in cells transfected with GluA1
and GluA1+CPT1C, respectively. Our results show that whole-
cell current density measured at −80mV from cells expressing
GluA1 together with CPT1C was higher than those currents
recorded for GluA1 alone (Figure 2C; 66.97 ± 18.77 pA/pF for
GluA1 vs. 159.4 ± 39.43 pA/pF for GluA1+CPT1C; p = 0.0431;
Mann–Whitney U-test; n = 11 and 8 respectively).
For the coimmunoprecipitation experiments performed in
Figure 1 we used a GFP-tagged form of CPT1C due to the
lack of a good commercially available anti-CPT1C antibody.
To be consistent between experiments we carried out the
electrophysiological experiments with the GFP-tagged form of
CPT1C. However, we could not rule out that the fused GFP could
somehow account for the whole-cell current increase seen in our
recordings. To exclude that possibility we repeated our experi-
ments with a non-tagged form of CPT1C protein (CPT1C-pIRES;
see methods). We found a similar increase in the current den-
sity to that obtained with the GFP-tagged form (data not shown).
Further, the effect of CPT1C on GluA1 could be due to a general
CPT1 activity or feature and not due to the specific interaction of
the isoform CPT1C with GluA1. To test this possibility we over-
expressed the most ubiquitous form of CPT1, CPT1A, together
with GluA1. We found similar current density values to those
obtained with GluA1 alone (Figure 2C; 66.97 ± 18.77 pA/pF for
GluA1 vs. 78.69 ± 37.10 pA/pF for GluA1+CPT1A; p = 1.0000;
Mann–Whitney U-test; n = 11 and 5 respectively). This demon-
strates the specificity of the CPT1C effect on AMPAR-mediated
currents.
CPT1C is also present in AMPAR complexes isolated with
GluA2 antibody (Schwenk et al., 2012 and Figure 1B). Therefore
we investigated whether the effect of CPT1C on GluA2 subunit
was similar to the one seen for GluA1 subunits by doing whole-
cell density current experiments in GluA2 homomeric AMPARs.
Unlike GluA1, Figure 2D shows that there was no increase in cur-
rent density when CPT1C was co-expressed with GluA2 in tsA201
cells (61.85 ± 16.48 pA/pF for GluA2 vs. 52.28 ± 20.27 pA/pF for
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FIGURE 2 | CPT1C specifically increases glutamate-evoked currents of
GluA1-containing AMPARs. (A) Whole-cell current-voltage (IV)
relationship for a tsA201 cell expressing GluA1 homomeric receptors. The
IV plot was obtained by ramping membrane potential from −80 to +80mV
at a rate of 160mV/ s in the presence of 1mM glutamate plus 25μM CTZ
to avoid receptor desensitization. 100μM spermine was added to the
pipette solution. Inset represents the voltage protocol used. (B) Same as
(A) but for a cell expressing GluA1 plus CPT1C-GFP (CPT1C). (C) Average
normalized currents at -80mV for GluA1 alone or together with CPT1C or
CPT1A. GluA1 current density (-pA/pF) was increased by co-expression
with CPT1C (∗p < 0.05; Mann–Whitney U-test) but was unaffected by
CPT1A co-expression (p > 0.05; Mann–Whitney U-test). Numbers in bars
denote the number of recordings. (D) Average current density for GluA2
alone or with CPT1C (p > 0.05; Mann–Whitney U-test). Numbers in bars
denote the number of recordings. (E) Whole-cell IV in the same conditions
as (A) but for a cell expressing GluA1/GluA2 heteromeric AMPARs.
Rectification index (RI; I+60mV/I−60mV) gives a read-out of GluA2
incorporation. (F). Same as (E) but for a cell expressing GluA1/GluA2 plus
CPT1C. (G). Average normalized currents at −80mV for GluA1/GluA2
AMPARs with or without CPT1C. GluA1/A2 current density (-pA/pF) was
increased by co-expression with CPT1C (∗p < 0.05; Mann–Whitney U-test).
Numbers in bars denote the number of recordings. (H). Average RI for the
cells recorded in both conditions showing no differences between groups.
GluA2+CPT1C; p = 0.2991; Mann–WhitneyU-test; n = 7 and 9
respectively).
Most of glutamatergic neurons in CNS express GluA2-
containing AMPARs either with GluA1, GluA3 or GluA4
(Gallo et al., 1992; Kondo et al., 1997; Lu et al., 2009;
Reimers et al., 2011). Thus we decided to evaluate whether
GluA1/GluA2 heteromeric receptors currents were similarly
affected by CPT1C. Figures 2E–G shows that CPT1C was able
to increase current density from heteromeric receptors (152.1 ±
23.94 pA/pF for GluA1/GluA2 vs. 246.9 ± 30.26 pA/pF for
GluA1/GluA2+CPT1C; p = 0.0236; Mann–Whitney U-test; n =
19 and 18 respectively). In these experiments, in order to favor
GluA2 presence in the receptor we transfected in a 1:2 ratio
(GluA1:GluA2) and the GluA1 plasmid expressed the mCherry
protein (see methods) thus allowing the recording of GluA1-
containing receptors. In fact, for both conditions, the red fluo-
rescence patched cells displayed linear responses, which were not
different between both groups confirming the presence of GluA2
(Figure 2H; RI+60/−60= 0.84 ± 0.04 without CPT1C vs. 0.82 ±
0.04 with CPT1C; p = 0.8910; Mann–Whitney U-test; n = 19
and 18 respectively).
CPT1C DOES NOT ALTER GATING PROPERTIES OF AMPARs
In the current density experiments described above we found
a significant increase in the glutamate-evoked GluA1-mediated
currents when CPT1C was present. The total amount of current
carried by a given population of receptors depends on several fac-
tors, which include the single channel conductance, the kinetics,
the open probability of the receptor and the number of receptors
contributing to the current. Any alteration in these parameters
might result in changes in the current magnitude. So, one pos-
sibility would be that CPT1C could modulate the single channel
conductance or open probability of AMPARs either by a direct
interaction (Soto et al., 2007, 2014; Suzuki et al., 2008; Coombs
et al., 2012; Shelley et al., 2012) or indirectly by phosphoryla-
tion (Derkach et al., 1999; Banke et al., 2000; Kristensen et al.,
2011). So, we decided to investigate the mechanisms contribut-
ing to the current increase observed in AMPARs together with
CPT1C. To determine whether AMPAR single channel conduc-
tance was altered by CPT1C we transfected GluA1 either alone or
together with CPT1C in tsA201 cells and applied fast applications
of glutamate (10mM; 100ms duration; 1 kHz) onto out-side out
patches followed by non-stationary fluctuation analysis of the
glutamate-evoked responses.
Figures 3A,B show typical responses for GluA1 homomers
alone (Figure 3A) or together with CPT1C (Figure 3B). The sin-
gle channel conductance of GluA1 homomers was not altered
when co-expressed with CPT1C (Figure 3C; 16.53 ± 1.07 pS for
GluA1 alone vs. 17.07 ± 1.31 pS for GluA1+CPT1C; p = 0.8095,
Mann–Whitney U-test; n = 17 for both). CPT1C did not alter
peak open probability (Po,peak) of AMPARs (Figure 3D; 0.43 ±
0.04 for GluA1 vs. 0.40 ± 0.05 for GluA1+CPT1C; p = 0.6052,
Mann–Whitney U-test; n = 17 for both). Similarly, the AMPARs
kinetics measured as the desensitization decay time constant (see
methods) were not changed (Figure 3E; 2.32 ± 0.18ms for cells
expressing GluA1 alone vs. 2.53 ± 0.17ms for cells expressing
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FIGURE 3 | CPT1C does not alter AMPAR gating properties. (A) Current
activated by rapid application of 10mM glutamate (100ms, −60mV) to an
outside-out patch from a tsA201 cell expressing GluA1 alone. Gray trace
represents a single response and black line the average of 37 responses.
Inset shows the current variance vs. mean current plot for this patch. The
weighted mean single-channel conductance estimate for this record was 17.3
pS. (B) Same as (A) but for a cell expressing GluA1 plus CPT1C-GFP
(CPT1C). Black line is the average of 38 responses. Inset: current variance vs.
mean current plot for this patch giving a weighted mean single-channel
conductance of 16.7 pS. (C–F) CPT1C has no influence on either weighted
single channel conductance (C; pS), peak open probability (D; Po,peak),
desensitization kinetics (E; τdes) or rectification index (F; I+60mV/I−60mV) of
GluA1 homomeric AMPARs. P > 0.05, Mann–Whitney U-test for all groups.
Numbers in bars denote the number of recordings.
GluA1+CPT1C; p = 0.3112, Mann–Whitney U-test; n = 18 for
both). Since AMPAR auxiliary subunits attenuate the strong block
by polyamine of calcium permeable AMPARs (CP-AMPARs)
(Soto et al., 2007, 2009), we evaluated if CPT1C was able to have
a similar effect. We therefore measured the rectification index
(RI) at +60/–60mV (see methods) from the IV ramps exper-
iments (Figures 2A–C), however we did not see any alteration
in the strong inwardly rectifying IV relationship of CP-AMPARs
(Figure 3F; 0.051 ± 0.009 for cells expressing GluA1 alone vs.
0.049 ± 0.011 for cells expressing GluA1+CPT1C; p = 0.8554,
Mann–Whitney U-test; n = 11 and 8 respectively).
Taken together, data from Figures 2, 3 show that glutamate-
evoked current density is increased by co-expression of CPT1C
in GluA1 expressing cells but not those expressing only GluA2
subunit. Nonetheless, GluA1 channel properties (single channel
conductance, peak open probability and desensitization kinetics)
are unaffected suggesting an increase in receptor number at the
cell surface. These results could also be indicating that both pro-
teins do not associate at the plasma membrane despite a larger
amount of current when CPT1C is co-expressed with GluA1.
AMPARs CO-LOCALIZE WITH CPT1C AT THE ER BUT NOT AT THE
PLASMA MEMBRANE
Our results show a functional effect of CPT1C on GluA1. This
effect though, seems not to be similar to that of “bona fide”
auxiliary subunits, which exert several modulatory effects on
AMPAR at the plasma membrane level (Jackson and Nicoll, 2011;
Shanks et al., 2012). Therefore, to study the presence or absence of
CPT1C at the cell surface, we visualized the location of the inter-
action between CPT1C and AMPAR subunits. With this aim, we
co-transfected cells with CPT1C-GFP and GluA1 or GluA2 and
performed immunofluorescence to differentially visualize surface
AMPARs (red in Figures 4A,B) and the total pool of AMPARs
subunits (blue in Figures 4A,B) by using confocal microscopy
(for details, see methods).
Results in Figures 4A,B using cell lines indicate that
CPT1C co-localize with both intracellular GluA1 and GluA2
(Figures 4A,B; light blue in left panels). Quantification of these
co-localizations using Manders Overlap coefficient (MOC; see
methods) is shown in Figure 4D (0.67 ± 0.14 for GluA1 and
0.59 ± 0.12 for GluA2; blue columns; n = 10). In fact, CPT1C
expression seems to be restricted to areas close to the nucleus and
with a reticular pattern (Figures 4A,B; green signal). Interestingly,
there is no co-localization of CPT1C with surface receptors con-
firming that the interaction does not take place at the cell-surface
(Figures 4A,B; right panels). Figure 4D (red columns) shows
MOC for CPT1C and surface GluA1 (0.13 ± 0.09; n = 10) or
surface GluA2 (0.11 ± 0.08; n = 10).
CPT1C has been described to co-localize with ER markers
in transfected cell lines and in neurons (Sierra et al., 2008;
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FIGURE 4 | GluA1 and GluA2 co-localize with CPT1C at intracellular
compartments but not at the plasma membrane. CPT1C does not
co-localize with the Golgi Apparatus marker GM-130. (A) Confocal image
showing co-localization of CPT1C-GFP (green) with GluA1 (dark blue signal
in left panel) in transfected tsA201 cells. Co-localization signal is displayed
as light blue (left panel). There is no co-localization between CPT1C (green)
and cell-surface GluA1 (red signal in right panel). Scale bar: 10μm.
(B) Confocal image showing co-localization of CPT1C (green) with GluA2
(dark blue signal in left panel) in transfected tsA201 cells. Co-localization
signal is apparent as light blue color (left panel). There is no co-localization
between CPT1C (green) and cell-surface GluA2 (red signal in right panel).
Scale bar: 10μm. (C) Co-localization (yellow signal in left panel) of
CPT1C-GFP with ER marker (pDsRed-KDEL). Lack of co-localization
(absence of yellow signal in right panel) of CPT1C (green) with the Golgi
Apparatus marker GM-130 (red) in transfected tsA201 cells. Scale bars:
10μm. (D) Representation of co-localization values quantified by Manders
Overlap Coefficient (MOC; see Methods) expressed as mean ± SEM. MOC
values for total GluAs and CPT1C (blue columns) were statistically different
(Continued)
FIGURE 4 | Continued
from surface GluAs and CPT1C (red columns; ∗∗∗p < 0.001 for both
comparisons; Mann–Whitney U-test; n = 10 for all conditions). MOC values
for CPT1C-ER marker (pDsRed-KDEL) show strong co-localization (yellow
bar). MOC values for CPT1C-GM130 (GA marker; green bar) were similar to
those of surface GluAs-CPT1C.
Carrasco et al., 2012). We confirmed this previous localiza-
tion of CPT1C in the ER in our expression system (Figure 4C;
left panel and Figure 4D; yellow column; MOC of 0.77 ±
0.04). Since GluA subunits dwell in the Golgi Apparatus dur-
ing posttranscriptional modifications (Greger et al., 2002) we
wondered if CPT1C and GluAs might interact at this level.
However, we found that CPT1C shows poor co-localization with
a Golgi Apparatus marker (GM-130) as shown in Figure 4C
(right panel) and Figure 4D (green column; MOC of 0.11± 0.05;
n = 10).
This data clearly demonstrates that GluA subunits are
together with CPT1C at the ER level but not at the plasma
membrane.
SURFACE EXPRESSION OF GluA1 IS INCREASED IN THE PRESENCE OF
CPT1C
Our results showing that AMPAR gating at the plasma mem-
brane level is not altered by CPT1C suggests that the increase in
whole-cell currents might be explained by an increased number
of receptors present at the cell surface.
To test this hypothesis we determined GluA1 surface
expression using immunofluorescence quantification. We
immunostained surface GluA1 in live transfected tsA201 cells
(Figures 5A,B; red signal). We then permeabilized the cells and
stained the total GluA1 pool (Figures 5A,B; blue signal). Given
the variability in expression levels we calculated the ratio of
the surface expression of GluA1 vs. the total expression level of
GluA1 for the same cell.
As shown in Figure 5C the normalized ratio surface to
total GluA1 was increased in cells co-expressing GluA1 and
CPT1C-GFP (100 ± 5.53% for cells expressing GluA1 alone vs.
160.6 ± 6.24% for cells expressing GluA1+CPT1C; p < 0.0001,
Mann–Whitney U-test; n = 84 and 90 cells respectively from
4 immunocytochemistry experiments for each condition). This
result indicates a possible role of CPT1C in increasing GluA1
trafficking to the cell surface.
We wanted to extend these findings by studying CPT1C
influence on surface expression of native AMPARs from neu-
ronal cultures. Hence, we carried out immunofluorescence
experiments in primary cortical neurons cultures at 10DIV
(Figures 5D–F). By using an equivalent methodology performed
with tsA201 cells, we measured the GluA1 surface to total
ratio in dendrites from GFP transfected neurons (Figure 5D)
compared with CPT1C-GFP overexpressed neurons (Figure 5E).
Figures 5D2–D4, E2–E4 show examples of the analyzed den-
drites. Neurons transfected with CPT1C increased the GluA1
surface to total ratio (100 ± 3.58 % for control GFP transfected
neurons vs. 118.8 ± 5.65 % for CPT1C-GFP transfected neurons;
p = 0.0226; n = 70 and 80 dendrites respectively from 3 different
cultures each; Figure 5F).
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FIGURE 5 | CPT1C enhances surface expression of GluA1. (A,B)
Representative single confocal images of tsA201 cells co-expressing GluA1
and GFP (A) or GluA1 and CPT1C-GFP (B). Surface GluA1 was labeled in live
cells with anti-GluA1-NT and Alexafluor 555 (red signal in the images).
Subsequently cells were permeabilized and total GluA1 expression level was
labeled with the same primary antibody but with Alexafluor 647 (blue signal
in the images). Scale bars: 20μm. (C) Quantification of the GluA1 surface to
total ratio normalized to GluA1, expressed as a percentage. GluA1 surface
expression was increased by co-expression with CPT1C (∗∗∗p < 0.001;
Mann–Whitney U-test). Data are means ± SEM. Numbers in bars denote the
number of cells quantified from 4 different immunofluorescence
experiments. (D) Example of a DIV 10 cortical neuron transfected with GFP.
Surface GluA1 was labeled in fixed cells with anti-GluA1-NT and Alexafluor
555 (red signal in the images). Subsequently cells were permeabilized and
total GluA1 expression level was labeled with the same primary antibody but
with Alexafluor 647 (blue signal in the images). D1: field image showing the
GFP in green, the surface GluA1 in red and the total GluA1 in blue. Scale bar:
50μm. D2: magnification of the dendritic boxed area in D1 for total GluA1.
D3: same as D2 but for surface GluA1. D4: overlay of intracellular and surface
GluA1 for box in D1. (E) Example of a DIV 10 cortical neuron transfected with
CPT1C-GFP in the same conditions as D. E1: field image showing the
CPT1C-GFP in green, the surface GluA1 in red and the total GluA1 in blue.
Scale bar: 50μm. E2: magnification of the dendritic boxed area in E1 for total
GluA1. E3: same as E2 but for surface GluA1. E4: overlay of total and surface
GluA1 for box in E1. (F) Quantification of endogenous GluA1 surface to total
ratio normalized to GFP transfected neurons, expressed as a percentage.
GluA1 surface to total ratio was increased by overexpression of CPT1C-GFP
(∗p = 0.0226; Mann–Whitney U-test). Data represent means ± SEM.
Numbers in bars denote the number of dendrites quantified from 3 different
cultures.
These results show that CPT1C favors the trafficking of
GluA1-containing AMPARs in both heterologous cells and
neurons.
CPT1C ENHANCING EFFECT ON SURFACE EXPRESSION AND CURRENT
DENSITY IS MEDIATED BY GluA1 C585
Our data suggest an effect of CPT1C on the trafficking of GluA1.
This effect could be performed by a chaperone-like activity of
CPT1C or by some posttranslational modification mediated by
this protein directly on GluA1. It has been demonstrated that
the posttranslational modification palmitoylation affects AMPAR
trafficking (Hayashi et al., 2005; Lin et al., 2009; Yang et al., 2009).
This modification consists in the reversible introduction of a lipid
palmitate in some specific cysteine residues present in proteins.
Given that it has been described that CPT1C can bind palmitoyl-
CoA (Sierra et al., 2008) we addressed the question whether the
observed increase in surface expression of GluA1 could be medi-
ated by changes in the palmitoylation state of GluA1 due to
CPT1C.
To check this possibility we first obtained two mutant forms
of GluA1 that cannot be palmitoylated at previously described
palmitoylable cysteine residues 585 and 811 (Hayashi et al., 2005)
by changing the cysteine for a serine (C585S or C811S; see meth-
ods). We also tested the double mutant form GluA1(C585,811S).
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Hence, we studied the effect of these mutations and their
co-expression with CPT1C-GFP in cell lines firstly using the
immunofluorescence quantification of surface receptors and also
studying the current density.
Figures 6A–C show confocal images of surface GluA1 quan-
tification experiments for GluA1 constructs alone (left panels)
and together with CPT1C (right images). Quantification of 3
immunocytochemistry experiments for each condition is pre-
sented in Figure 6D and Table 1. In parallel we carried out
whole-cell current density experiments as described in Figure 2
to directly assess the effect of CPT1C on the glutamate-evoked
currents of GluA1 mutants (Figure 6E and Table 2).
We replicated the immunofluorescence and electrophysiology
results obtained in Figures 2, 5 in parallel with the mutant forms
of GluA1. As previously found, CPT1C increased the surface/total
ratio of GluA1 (100.0 ± 4.86% for GluA1 vs. 182.6 ± 10.25%
for GluA1+CPT1C; p < 0.001; Figure 6D and Table 1) and the
current density of homomeric GluA1 (85.86 ± 21.95 pA/pF for
GluA1 vs. 155.5 ± 24.22 pA/pF for GluA1+CPT1C; p = 0.0334;
Figure 6E and Table 2).
We observed that in the absence of CPT1C, GluA1(C585S)
expression was enhanced at the cell surface by 1.97-fold com-
pared to native GluA1 (p < 0.001; Figure 6D and Table 1) and
that the glutamate-evoked current carried by GluA1(C585S) was
FIGURE 6 | GluA1 C585 is critical for the enhancement of current density
and surface expression by CPT1C. (A–C). Representative single confocal
images of tsA201 cells co-expressing different versions of GluA1 with (right
panels) or without (left panels) CPT1C-GFP. In the images, surface GluA1 is
shown in red and total GluA1 in blue. Scale bar: 50μm. (A) Native GluA1
co-expressing GFP (+GFP) as the control condition, or CPT1C-GFP (+CPT1C).
(B). Same as (A) but for cells expressing GluA1 containing the point mutation
C585S that abolishes palmitoylation at this residue. (C) Same as (A,B) but for
GluA1 with the point mutation C811S. (D) Quantification of the GluA1 surface
to total ratio normalized to GluA1, expressed as a percentage. GluA1 surface
expression was increased by co-expression of CPT1C for both GluA1 and
GluA1(C811S) (∗∗∗p < 0.001; Mann–Whitney U-test) but not for
GluA1(C585S). Non-palmitoylable forms of GluA1 increased surface
expression of the receptors when compared to wild-type GluA1 (WT)
(###p < 0.001; Mann–Whitney U-test). Numbers in bars denote the number
of cells quantified from 3 different immunofluorescence experiments.
(E) Averaged normalized currents at −80mV for different versions of GluA1
alone or together with CPT1C. Current density (-pA/pF) was increased by
co-expression of CPT1C with native GluA1 (WT) or mutant GluA1(C811S)
(∗p < 0.05; Mann–Whitney U-test) but not for GluA1(C585S). GluA1(C585S)
increased the current density when compared to native GluA1 (##p < 0.01;
Mann–Whitney U-test). Numbers in bars denote the number of recordings.
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increased to the same degree (2.15-fold; p = 0.0041, Figure 6E
and Table 2). These results are in keeping with previous find-
ings (Hayashi et al., 2005). Interestingly, the effects of CPT1C
co-expression and the GluA1(C585S) mutation were not additive.
Table 1 | Normalized fluorescence ratio (% of surface vs. total) values.
Receptor Normalized n p-value p-value
fluorescence (vs. no (vs.
ratio (Surface/ CPT1C) GluA1)
Total) (%)
GluA1 − 100.0±4.86 88
+CPT1C 182.6±10.25 91 <0.001
GluA1(C585S) − 196.9±9.41 63 <0.001
+CPT1C 191.3±9.47 67 0.4876
GluA1(C811S) − 146.5±7.08 71 <0.001
+CPT1C 198.2±8.99 70 <0.001
GluA1(C585,811S) − 208.2±11.55 35 <0.001
+CPT1C 208.1±7.87 37 0.9014
Transiently transfected tsA201 cells for different conditions were immunostained
against surface and total GluA1 (see methods) and the ratio of GluA1 surface
expression vs. GluA1 total expression was calculated and normalized to that
of GluA1 control group. Three different immunofluorescence experiments were
performed for each condition and the total number of analyzed cells is shown (n).
Each p value is from a Mann–Whitney U-test comparing normalized fluorescence
values of the distinct GluA1 receptors in the absence or presence of CPT1C
(“vs. no CPT1C” column) or normalized fluorescence values of mutant versions
of GluA1 against wild type GluA1 (“vs. GluA1” column).
Table 2 | Current density values for GluA1 mutants with or without
CPT1C.
Receptor Current n p-value p-value
density (vs. no (vs.
(pA/pF) CPT1C) GluA1)
GluA1 − 85.86±21.95 16
+CPT1C 155.5±24.22 13 0.0334
GluA1(C585S) − 184.3±19.19 13 0.0041
+CPT1C 198.0±41.25 11 0.7721
GluA1(C811S) − 97.32±20.26 12 0.4166
+CPT1C 213.0±36.12 11 0.0210
GluA1(C585,811S) − 153.8±14.58 10 0.0143
+CPT1C 178.9±34.89 10 0.8534
Transiently transfected tsA201 cells for different conditions were whole-cell
patch clamped and voltage ramps from −80 to +80 mV were applied (see meth-
ods for details). The maximum current at −80 mV was then normalized against
the cell capacitance to obtain the current density values (-pA/pF). The total num-
ber of recorded cells is shown (n). Each p value is from a Mann–Whitney U-test
comparing current density values for each GluA1 receptor in the absence or pres-
ence of CPT1C (“vs. no CPT1C” column) or current density values of mutant
versions of GluA1 against wild type GluA1 (“vs. GluA1” column).
Specifically, CPT1C did not further increase the surface expres-
sion of GluA1(C585S) (p = 0.4876, Figure 6D and Table 1) or
the current density of GluA1(C585S) (p = 0.7721, Figure 5E and
Table 2). Likewise CPT1C did not vary the high surface expres-
sion or further enhance current density of the double mutant
GluA1(C585,811S) (p = 0.9014 and p = 0.8534, Tables 1, 2).
This suggests that C585 might be crucial in the CPT1C effect on
trafficking of GluA1.
In addition, GluA1(C811S) surface expression was also
enhanced compared to GluA1 (p < 0.0001; Figure 6D
and Table 1). Nevertheless, although significantly differ-
ent from GluA1, GluA1(C811S) seems to be less efficiently
expressed at the membrane surface compared the other GluA1
mutants (p < 0.001 for GluA1(C811S) vs. GluA1(C585S) or
GluA1(C585,811S); Mann–Whitney U-test for both compar-
isons) and clearly GluA1(C811S) was not able to increase current
density compared with GluA1 (p = 0.4166, Figure 6E and
Table 2). However CPT1C co-expression does have an effect
on both GluA1(C811S) surface expression (146.5 ± 7.08 % for
GluA1(C811S) vs. 198.2 ± 8.99 % for GluA1(C811S)+CPT1C;
p < 0.001; Figure 6D and Table 1) and current density (97.32 ±
20.26 pA/pF for GluA1(C811S) vs. 213.0 ± 36.12 pA/pF for
GluA1(C811S)+CPT1C; p = 0.0210; Figure 6E and Table 2).
Finally, the effect of CPT1C on GluA1(C811S) is equiva-
lent to the effect of the C585S mutation alone in terms of
both, surface expression (Figure 6D; p = 0.9623) and current
density (Figure 6E; p = 0.6430). These results suggest that the
enhancing effect of CPT1C on surface expression and current
density is mediated by a modification of cysteine 585 of GluA1
subunits.
PALMITOYLATION STATE OF GluA1 IS UNAFFECTED BY CPT1C
OVEREXPRESSION
It has been previously demonstrated that palmitoylation of GluA1
at the C585 residue retains AMPARs in the Golgi Apparatus
(Hayashi et al., 2005) implying that depalmitoylated GluA1 at
C585 traffics more efficiently to the plasma membrane. Our
data corroborate these findings since the number of receptors at
the surface in the mutant C585S (where cysteine 585 cannot be
palmitoylated) is increased. Interestingly, the surface expression
of GluA1(C585S) is approximately the same as GluA1(C811S)
expressed with CPT1C (where CPT1C effect can only be on the
intact cysteine 585). This result seems to point to CPT1C being a
potential depalmitoylating enzyme of GluA1.
To test this hypothesis we analyzed the palmitoylation level
of GluA1 when expressed in the absence or presence of CPT1C.
We performed the Acyl Biotin Exchange assay as described in
Brigidi and Bamji (2013) (see methods). This assay allows the
replacement of a pre-existing palmitate bound to cysteines of a
given protein with a biotin group. The biotin is subsequently
detected with streptavidin to give a read-out of palmitoylation
levels. Therefore we transfected tsA201 cells with GluA1 alone or
GluA1 plus CPT1C-GFP. Palmitoylation levels of GluA1 in the
absence of CPT1C were equivalent to GluA1 palmitoylation lev-
els in the presence of CPT1C (Figure 7A; upper panel, second and
forth lane and Figure 7B). Immunoprecipitated GluA1 was quan-
tified to normalize palmitoylation levels (Figure 7A; lower panel).
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FIGURE 7 | GluA1 palmitoylation state is not altered by CPT1C and does
not affect the interaction with GluA1. (A) Palmitoylation levels of GluA1
alone (GluA1) and together with CPT1C-GFP (GluA1+CPT1C), in transfected
tsA201 cells, detected by means of Acyl-Biotin Exchange (ABE). The
thiol-biotinylated immunoprecipitates of GluA1 following the ABE assay for
both transfected conditions were subjected to SDS-PAGE. Palmitoylation of
GluA1 can only be detected in plus-hydroxilamine (+HAM) samples. Minus
-HAM samples control non-specific incorporation of biotin. GluA1
palmitoylation levels (top) were detected by Western blotting with
streptavidin-HRP (palmitoylation). After stripping the membranes the total
amount of immunoprecipitated GluA1 was detected by Western blotting with
anti-GluA1-NT antibody (anti-GluA1, bottom). (B) Quantification of
palmitoylation levels for GluA1 alone (open circles) or GluA1 plus CPT1C
(filled circles) in tsA201 cells. Ratio of palmitoylated GluA1 to total GluA1 for
each single experiment is shown together with mean (discontinuous
horizontal lines) and SEM (continuous vertical lines) (p > 0.05; Mann–Whitney
U-test; n = 8 for both). (C) Co-IP of the membranous fraction of tsA201 cells
co-expressing GluA1 wild type or non-palmitoylable mutants—GluA1(C585S),
GluA1(C811S), and GluA1(C585,811S)—together with CPT1C-GFP. The
interaction between CPT1C and GluA1 is not dependent on palmitoylation of
C585 or C811 residues. As negative controls GluA1 was co-expressed with
an empty plasmid expressing GFP alone (first lanes of the boxes) and
CPT1C-GFP was co-expressed with an empty pDsRed (second lanes from
the boxes). Transfected cells were lysed and membranes were solubilized as
described in Figure 1 and methods. An input sample collected prior to
immunoprecipitation of these extracts is shown as “INPUT.” Inputs and
immunoprecipitated samples were separated and Western Blotted as
described in Figure 1. Immunoprecipitations were replicated three times.
Figure 7B display the single experiments ratio values of palmi-
toylated GluA1 vs. total GluA1 for both conditions where it can
be observed there is no significant difference (0.523 ± 0.084 for
GluA1 vs. 0.431± 0.11 for GluA1+CPT1C; p = 0.3228; n = 8 for
both).
Thus, by using this methodology we could not confirm the role
of CPT1C as a depalmitoylating enzyme.
Given that C585 seems critical to favor AMPARs trafficking but
its palmitoylation state is not changed by CPT1C we wondered if
the lack of palmitate group could perhaps interfere with the phys-
ical interaction between GluA1 and CPT1C. In order to check
if CPT1C ability to interact with GluA1 was eliminated when
residue 585 was non-palmitoylated, we did co-IP assays with the
GluA1(C585S) and CPT1C. As shown in Figure 7C, GluA1 and
CPT1C retained the ability to interact even when cysteines 585,
811 or both were mutated to non-palmitoylable forms. This result
indicates that the binding of both proteins depends on other
domains/residues and that palmitoylable C585 does not deter-
mine this interaction despite its importance in CPT1C effect on
trafficking properties of AMPARs.
DISCUSSION
In this study we describe a novel function of CPT1C in
regulating AMPAR surface expression in both heterologous
cells and neurons. In tsA201 cells CPT1C increases whole-cell
glutamate-evoked currents of homomeric GluA1 and het-
eromeric GluA1/GluA2 AMPARs. Moreover, CPT1C overexpres-
sion enhances the number of endogenous AMPARs trafficked
to the dendritic surface in rat cortical neurons. This trafficking
effect is specific to the brain isoform CPT1C since the canon-
ical CPT1 isoform also expressed in neurons (CPT1A) is not
able to increase GluA1 mediated currents. Additionally, CPT1C
modulation seems to be subunit specific since GluA2 homomeric
AMPARs are unaffected by CPT1C co-expression. Despite GluA1
and CPT1C coimmunoprecipitating, both proteins do not co-
localize at the plasma membrane level and no further biophysical
modulation of AMPARs by CPT1C exists. Finally, the palmitoy-
lable cysteine 585 of the GluA1 subunit seems to be crucial for
the CPT1C alteration of AMPARs trafficking properties although
no changes in the palmitoylation state of the receptor seem to
occur.
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ROLE OF CPT1C IN AMPARs TRAFFICKING
In our experiments, both current density and cell surface expres-
sion are increased when CPT1C is co-expressed with GluA1.
Despite this, GluA2 homomeric AMPARs seem not to be regu-
lated by CPT1C, while GluA2-containing AMPARs, which are the
most abundant form of AMPARs in neurons, are also sensitive to
CPT1C. This points to a significant role of CPT1C in the delivery
of GluA1 to the membrane in neurons. Indeed, the important
role of CPT1C in synaptic transmission is evident since CPT1C
knock-out mice have spatial learning problems, motor impair-
ment and hypoactivity (Carrasco et al., 2012, 2013). Alterations
in AMPAR-mediated signaling might underlie these phenotypes
since in immature spines AMPAR content is low compared with
mature synapses (Petralia et al., 1999). In fact, CPT1CKO animals
show poor dendritic spine maturation in hippocampal neurons
(Carrasco et al., 2012). In agreement with low AMPAR content
at synapse level, recent unpublished electrophysiological data by
our group has proved that synaptic transmission is altered in
CPT1C KO animals (submitted manuscript). In these animals the
lack of CPT1C translates to less efficient synaptic trafficking since
AMPAR-mediated mEPSCs in pyramidal hippocampal neurons
are diminished. All these findings reveal an important relation-
ship between CPT1C and AMPARs. Our data and the functional
evidence from the KO studies together with the ability of CPT1C
to interact with AMPARs (Figure 1 and Schwenk et al., 2012)
makes CPT1C a suitable candidate to be a regulating partner of
AMPARs and an important protein for the correct function of
AMPARs.
SUBUNIT SPECIFICITY OF CPT1C MODULATION
Our coimmunoprecipitation experiments showed direct inter-
action of CPT1C with both GluA1 and GluA2 subunits.
Nevertheless the observed effects of CPT1C on whole-cell cur-
rents and surface expression were specific for GluA1-containing
AMPARs since the results were not replicated in cells express-
ing GluA2 homomeric AMPARs. GluA1 and GluA2 subunits have
distinct features in their structure including the Q/R site and the
intracellular C-terminal domain, which translate to important
functional differences (Traynelis et al., 2010). Remarkably, the
important C585 palmitoylable residue in GluA1 (C610 in GluA2)
for CPT1C effect is located +3 aminoacids from the crucial
Q/R site. Another significant difference is the short C-terminal
domain of GluA2. In fact, variations in the C-tails and the Q/R
site between both isoforms determine different trafficking prop-
erties of GluA1 and GluA2 (Greger et al., 2002; Henley and
Wilkinson, 2013). Therefore, it could be possible that a differen-
tial modulation by CPT1C was dependent on the C-tail length,
the specific C-terminal aminoacid composition or on Q/R site
editing state of AMPARs. The majority of AMPARs in the CNS
are heteromeric combinations (Lu et al., 2009; Traynelis et al.,
2010) and trafficking properties are determined by the domi-
nant effect of long forms of AMPARs (Henley and Wilkinson,
2013). Our results are in line with this dominant effect of
long forms. However, it remains to be studied whether other
features of GluAs account for the subunit selectivity. Future
experiments with other AMPAR forms might unravel the sub-
unit features accounting for the specific modulation of CPT1C.
Moreover, it would be interesting to investigate whether CPT1C
protein similarly modulates AMPARs together with auxiliary
subunits.
It is noteworthy that the effect of CPT1C on GluA2-containing
heteromeric AMPARs and native AMPARs—mostly heteromeric
combinations containing GluA2—is less pronounced than the
one observed for GluA1 homomeric AMPARs. Perhaps the 2-fold
enhancement of GluA1 density at the cell membrane could be
partially occluded in GluA2-containing receptors due to gener-
ally better trafficking properties of heteromeric combinations.
Indeed, the current density values we obtained for heteromeric
receptors were higher than for homomeric receptors (either
GluA1 or GluA2). This reflects the fact that heteromeric com-
binations of AMPARs are favored at the expense of homomeric
receptors when both subunits are present during the synthe-
sis process at the ER (Cull-Candy et al., 2006). The enhanced
trafficking of heteromeric combinations might translate into a
less evident CPT1C influence on GluA2-containing receptors.
Alternatively, stoichiometry might be an important determi-
nant in CPT1C effect. This possibility could be studied in the
future.
CPT1C IS NOT A GENUINE AUXILIARY SUBUNIT OF AMPARs
From our results, it looks like that this new AMPAR interactor
has a putative role in the delivery of AMPAR subunits to the cell
surface. It has been described that many other AMPAR inter-
acting proteins control AMPAR trafficking (Palmer et al., 2005;
Anggono and Huganir, 2012; Lu and Roche, 2012). This is the
case for auxiliary AMPAR subunits such as the TARPs that affect
the channel properties of AMPARs while also playing an impor-
tant role in surface trafficking (Nicoll et al., 2006). CNIH proteins
also increase AMPARs surface expression (Schwenk et al., 2009)
and modify the behavior of AMPARs both in expression sys-
tems and in neurons (Kato et al., 2010b; Coombs et al., 2012).
Conversely this is not the case for CPT1C, as we have shown that
this protein does not alter GluA1 channel properties. This fact is
supported by the confocal imaging experiments where we could
not see any co-localization between CPT1C and surface GluA1.
Consequently CPT1C cannot be considered a TARP-like “bona
fide” auxiliary subunit and it seems that its role is restricted to
controlling AMPARs trafficking.
CPT1C AND AMPARs INTERACT AT THE ER LEVEL
Even though CPT1C does not associate with AMPAR subunits at
the plasma membrane level, it is clear that both proteins interact
at some stage of the AMPAR synthesis pathway (Schwenk et al.,
2012 and Figures 1, 4). The fact that CPT1C shows a clear ER
pattern (Figures 4C–D; Sierra et al., 2008; Carrasco et al., 2012)
makes this organelle a meeting point for both proteins where
CPT1C could posttranslationally modify AMPARs accounting
for the increased traffic to plasma membrane. Further, our co-
localization studies also demonstrate that CPT1C does not seem
to interact with GluA1 outside of the ER at all, as CPT1C does not
co-localize with the Golgi Apparatus marker GM-130. Thus, our
results suggest that the effect of the interaction of CPT1C/GluA1
might take place exclusively at the ER level. They also point out
that the complex CPT1C-AMPAR would dissociate at some stage
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before AMPARs subunits move forward to the Golgi during their
biosynthesis.
MECHANISMS UNDERLYING CPT1C MODULATION OF AMPARs: ROLE
OF CYSTEINE 585 OF GluA1
AMPAR subunits are subject to several posttranslational mod-
ifications during biosynthesis that affect the trafficking of the
receptors to the cell surface. This is the case for the reversible
palmitoylation of AMPARs. All four AMPA receptor subunits are
palmitoylated at two conserved sites, (C585 and C811 in GluA1)
and palmitoylation/depalmitoylation of these two residues deter-
mine AMPARs trafficking properties (Hayashi et al., 2005; Lin
et al., 2009; Yang et al., 2009). Given that CPT1s have palmi-
toylCoA as a substrate it seemed plausible to consider whether
CPT1C was involved in a modification such as protein palmi-
toylation/depalmitoylation, thus potentially affecting AMPARs
surface expression.
When studying the role of cysteine residues in CPT1C effect,
we found that C585S mutation alone increased whole-cell cur-
rents and surface expression of GluA1 by 2-fold. These results are
in accordance with previous ones demonstrating that depalmi-
toylation of AMPARs at C585 acts as a triggering signal for
receptor forward trafficking (Hayashi et al., 2005). Interestingly,
in the presence of CPT1C, the GluA1(C585S) no longer increased
receptor trafficking. This points toward a crucial role of C585
residue for the CPT1C effect. This is confirmed by the fact that
the GluA1(C811S) mutant is modulated by CPT1C to the same
degree as GluA1 ruling out the involvement of C811 residue.
Moreover the fact that CPT1C increases GluA1(C811S) traffick-
ing to the same extent as GluA1(C585S) alone or with CPT1C
suggests that the effect of CPT1C is dependent on the C585
residue.
Finally, our findings show that GluA1(C811S) increases sur-
face expression when detected by immunofluorescence but cur-
rent density is not increased in the same extent. This might
be explained due to a different number of cells analyzed with
each technique. Despite that discrepancy, the significant incre-
ment in both parameters when CPT1C is together with GluA1
(C811S) indicates that GluA1 C811 is not crucial for the CPT1C
effect.
CPT1C DOES NOT ALTER GluA1 PALMITOYLATION STATE
Given that CPT1C produces an increase in GluA1 surface expres-
sion to the same extent as the non-palmitoylable form of
GluA1(C585S), we hypothesized that the effect of CPT1C on
GluA1 subunits could be via depalmitoylation of C585. However,
the palmitoylation state of GluA1 seems to be unaffected by co-
expression with CPT1C, at least when detecting palmitoylation
levels with the ABE assay. A possible issue with this methodology
might be that the ABE assay not only detects palmitoylation but
also other S-acylation modifications of GluA1, which have not yet
been described. Therefore other techniques might be necessary to
detect the palmitoylation levels of GluA1 C585 unambiguously.
Alternatively, a necessary depalmitoylation process performed in
the ER by CPT1C could be counteracted by additional palmi-
toylation of the receptor at other cell locations, thus making it
difficult to detect changes in the palmitoylation state. Therefore,
this hypothesis should be closely examined with future specific
refinements of palmitoylation assays.
HOW CAN CPT1C MODULATE AMPARs TRAFFICKING?
Though it appears that CPT1C does not depalmitoylate GluA1,
the involvement of cysteine 585 is clear. It is possible therefore
that the role of C585 is not related to the palmitoylation capacity
of the amino acid. Perhaps the physical interaction of CPT1Cwith
GluA1 masks the palmitate on this residue (or produces a confor-
mational change in GluA1) facilitating its exit from the ER and
the forward movement toward the Golgi. If that was the case, the
masking would not be due to a direct interaction of CPT1C with
the palmitate of C585 from GluA1, as both proteins still inter-
act in the absence of this palmitate group. Otherwise, it may be
possible that CPT1C acts as a chaperone during the synthesis of
GluA1 and this chaperone effect could be related to the ER palmi-
toylation of C585. It has been described for other proteins (for
instance the yeast polytopic membrane protein chitin synthase—
Chs3) that the parallel action of palmitoyl acyl thioesterases and
chaperones is necessary to achieve the correct folding and export
from the ER (Lam et al., 2006) suggesting a relation between
palmitoylation state and chaperone activity.
To gain insight into CPT1C modulation of AMPAR it would
be important to elucidate the domains participating in the inter-
action. The topology of CPT1A shows that N- and C-terminal
domains face the cytoplasm (Fraser et al., 1997). Presumably
CPT1C displays the same topology thus restricting the interaction
with AMPAR subunits to their C-terminal tail or transmembrane
domains.
CPT1C AND DISEASE
Even though CPT1C expression is restricted to the brain in
healthy individuals, it functions as a stress-responsive gene under
a variety of conditions, as its mRNA is up-regulated in cell lines
from several different tissues as well as in mice following expo-
sure to any one of a number of p53-activating stresses (Reilly and
Mak, 2012). Therefore, it is suggested that CPT1C promotes can-
cer cell survival and tumor growth and it has been proposed as a
new therapeutic target in cancer treatment. It is noteworthy that
recent studies report an aberrant expression of CPT1C in gliomas
(Cirillo et al., 2014; Wakamiya et al., 2014). These findings high-
light the importance of unraveling the molecular mechanisms of
CPT1C, which could be of great interest across a range of fields,
for example in the study of new anticancer therapies and new
diagnostic or prognostic markers.
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